Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × talazoparib × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 39 Everolimus 31 Magnetic Resonance Spectroscopy 15 lanreotide 13 gallium Ga 68 dotatate 12 Octreotide 12 Temozolomide 11 Capecitabine 11 Nivolumab 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 surufatinib 9 pembrolizumab 8 cabozantinib 8 Positron Emission Tomography Computed Tomography 8 3-Iodobenzylguanidine 8 Sunitinib 7 Specimen Handling 7 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Lutetium-177 6 90Y-octreotide, DOTA-Tyr(3)- 6 telotristat ethyl 5 pasireotide 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 Carboplatin 5 Bevacizumab 5 olaparib 4 copper dotatate CU-64 4 avelumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡